VANCOUVER, British Columbia, May 14, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced its financial and operating results for the first quarter ended March 31, 2013 and provided a corporate update.
"Last month, we were pleased to present positive data from the dose escalation portion of our TKM-PLK1 Phase I clinical trial conducted in a population of advanced cancer patients with solid tumors. The data generated demonstrated that TKM-PLK1 showed encouraging signs of drug activity with RNAi activity confirmed in tumor biopsy. We were encouraged that two patients enrolled with gastrointestinal carcinoid (neuroendocrine) cancer, both responded to treatment with TKM-PLK1, and building on these results, we plan to initiate a Phase II clinical trial in patients with previously treated gastrointestinal carcinoid (neuroendocrine) cancer in the second half of 2013," said Dr. Mark J. Murray, Tekmira's President and CEO.
"Our successful collaboration with the U.S. Department of Defense's JPM-TMT program is ongoing, with recent modifications to our approximately $140 million contract, which will support development plans that integrate advancements in our lipid nanoparticle (LNP) formulation and manufacturing technologies, while providing additional funding for the TKM-Ebola program," added Dr. Murray."We are actively working to grow the number of collaborators using our technology, including pharmaceutical, biotechnology and agricultural companies. We also anticipate some near-term milestones from existing partners, including Alnylam, which has guided that it will present initial data from its ALN-TTR02 Phase II trial in mid-2013 and is on track to start a Phase III pivotal trial for ALN-TTR02 by the end of 2013. Tekmira expects to receive $10 million in milestone payments from Alnylam in 2013," stated Dr. Murray. Corporate Update and Highlights Tekmira's Products TKM-PLK1, Tekmira's Lead Oncology Therapeutic Tekmira's lead oncology product candidate, TKM-PLK1, targets PLK1 (polo-like kinase 1), a protein required for tumor cell proliferation and a validated oncology target. Inhibition of PLK1 expression prevents the tumor cell from completing cell division, resulting in cell cycle arrest and death of the cancer cell.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV